Search results

Technologies 2

• DoriVac: Boosting Antigen-specific Immune Responses with DNA Origami-Based Vaccines
  Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens.
• Implantable Cancer Vaccine
  The implantable cancer vaccine is an aspirin-sized disc that is implanted under the skin and serves as an artificial lymph node, recruiting and training a patient's own immune cells to find and kill their cancer cells. It was validated in a Phase I clinical trial at the Wyss Institute, and is currently being developed by Novartis to treat melanoma.

Collaborations 1

• i3 Center: Biomaterials to Create T Cell Immunity
  Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.

News 14

View all

• Community
  
  Yang (Claire) Zeng on Developing DoriVac, the Next Generation of Vaccine Delivery Technology
  September 28, 2022
• Research Spotlights
  
  Activating STING could make brain tumors more susceptible to treatment
  July 14, 2022
• Research Spotlights
  
  New cancer vaccine delivers double punch to tumors
  May 27, 2022

Multimedia 3

• 

  Video/Animation
  How can we train the immune system to fight cancer?
  The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient’s own immune cells on-site to kill cancer cells. This revolutionary immuno-material technology was tested in a Phase I clinical trial with promising results and is currently licensed by Novartis as an immunotherapy to treat specific tumor types. Credit: Wyss Institute at Harvard...

• 

  Video/Animation
  DoriVac: Square Block DNA Origami Vaccine
  This animation explains how DoriVac leverages DNA origami nanotechnology and immune activators to stimulate stronger and long-lasting immune responses against cancer and potentially infectious diseases. Credit: Wyss Institute at Harvard University

• 

  Audio/Podcast
  Immunoengineering with Dave Mooney – BIOS Podcast
  Wyss Core Faculty member Dave Mooney is a leader in the fields of biomaterials, mechanotransduction, drug delivery, tissue engineering and immunoengineering. He is interested in understanding how cells sense signals in their environment and how this alters cell behavior. His laboratory develops biomaterials that exploit these signals to regulate specific cells and their function. They...